IGF-1 DES (1-3)

§01Summary

IGF-1 DES (1-3), also known as des-(1-3)-IGF-1, is a naturally occurring truncated form of insulin-like growth factor 1 (IGF-1) in which the first three amino acids at the N-terminus have been removed. This modification gives the peptide a distinct biological profile compared to full-length IGF-1: because IGF-binding proteins (IGFBPs) can no longer sequester it, des-(1-3)-IGF-1 maintains greater free availability at cell surface receptors, which appears to translate into enhanced potency in promoting cell growth, protein synthesis, and tissue repair¹⁶.

In early laboratory studies, des-(1-3)-IGF-1 has been reported to stimulate DNA synthesis, increase protein accumulation, and reduce protein breakdown more effectively than native IGF-1 or IGF-2, effects attributed to its resistance to IGFBP inhibition rather than to higher intrinsic receptor affinity¹⁶. Research into its potential roles in muscle maintenance, metabolic health, and tissue regeneration is an active area of scientific investigation, with the current evidence base built primarily on biochemical and cell-based studies. Human clinical data are still emerging, and the peptide's therapeutic applications across indications are actively being explored.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

IGF-1 DES (1-3) is a naturally occurring variant of insulin-like growth factor 1 generated by proteolytic cleavage of the N-terminal tripeptide (glycine-proline-glutamate) from the full-length 70-amino acid IGF-1 molecule. This truncation preserves the core receptor-binding domains of IGF-1, allowing the peptide to engage the type 1 IGF receptor (IGF-1R) and activate downstream mitogenic and anabolic signaling cascades, including the PI3K/AKT/mTOR and RAS/MAPK/ERK pathways that regulate cell survival, proliferation, and protein synthesis.

The defining pharmacological distinction of des-(1-3)-IGF-1 relative to native IGF-1 lies in its interaction — or rather, lack thereof — with insulin-like growth factor binding proteins (IGFBPs). IGFBPs are a family of six high-affinity carrier proteins that bind the majority of circulating IGF-1 (>99% in plasma), restricting its availability to tissue IGF-1R. The N-terminal tripeptide of native IGF-1 contributes substantially to IGFBP binding affinity. Its removal in des-(1-3)-IGF-1 results in markedly reduced IGFBP binding, leaving a greater free fraction of the peptide accessible to cell surface receptors¹⁶. In vitro studies demonstrated that IGFBPs potently inhibited the biological activities of native IGF-1 and IGF-2 — including DNA synthesis, protein accumulation, and reduction of protein breakdown — but exerted no measurable inhibitory effect on des-(1-3)-IGF-1¹⁶. This finding establishes that the enhanced biological potency of des-(1-3)-IGF-1 is a consequence of IGFBP resistance rather than intrinsically higher receptor affinity.

Downstream of IGF-1R engagement, activated AKT promotes glucose uptake, protein synthesis via mTORC1, and suppression of proteolytic pathways including the ubiquitin–proteasome system, consistent with the observed reductions in protein breakdown rates reported for des-(1-3)-IGF-1¹⁶. The ERK arm contributes to mitogenic signaling and proliferative responses reflected in the DNA synthesis stimulation data. The pharmacokinetics of des-(1-3)-IGF-1 in vivo — including half-life, volume of distribution, and metabolic clearance — are active areas of investigation, with the peptide's reduced IGFBP binding expected to meaningfully alter its circulatory half-life and tissue distribution profile compared to native IGF-1.

§04Evidence & efficacy

The available evidence for IGF-1 DES (1-3) efficacy is currently anchored in in vitro biochemical studies. Des-(1-3)-IGF-1 has been reported to stimulate DNA synthesis and protein accumulation, and to reduce protein breakdown rates in chick embryo fibroblasts, with potency exceeding that of both native IGF-1 and IGF-2 under the same experimental conditions¹⁶. This enhanced efficacy appears to be mechanistically driven by the peptide's resistance to sequestration by IGF-binding proteins, which preserves a greater free fraction available to activate cell surface IGF receptors¹⁶. Human efficacy data across any indication are actively being investigated, and peer-reviewed clinical trial results are still emerging.

§05Safety

Human safety data for IGF-1 DES (1-3) are currently limited, as the available evidence is derived from in vitro mechanistic studies rather than clinical trials. The early biochemical work characterizing the peptide focused on its receptor binding and IGFBP-resistance properties rather than on toxicological endpoints¹⁶. No adverse events, contraindications, or drug interactions specific to IGF-1 DES (1-3) are reported in the studies analyzed.

The peptide's enhanced bioavailability relative to native IGF-1 — a consequence of its inability to bind IGFBPs¹⁶ — is a pharmacological feature that human safety studies will need to characterize in terms of tissue-specific effects. Safety profiling through formal preclinical and clinical programs is an active area of development.

§06History

Des-(1-3)-IGF-1 was first identified as a naturally occurring fragment of IGF-1, initially isolated from human colostrum and porcine brain tissue, where N-terminal proteolytic processing of full-length IGF-1 was observed. Interest in this truncated variant emerged in the 1980s alongside growing appreciation for the biological complexity of the IGF axis, particularly the regulatory role of IGF-binding proteins in modulating IGF bioavailability and activity.

A landmark biochemical study published in 1989 established the mechanistic basis for the peptide's distinct pharmacology, demonstrating that IGFBPs potently suppressed the biological activities of native IGF-1 and IGF-2 but had no inhibitory effect on des-(1-3)-IGF-1, explaining the latter's superior potency in cell-based assays¹⁶. This finding positioned the truncated peptide as a potentially more tissue-accessible IGF-1 analog and stimulated interest in its anabolic and growth-promoting applications.

Through the 1990s and 2000s, research expanded to explore the peptide's presence in the central nervous system and gastrointestinal tract, where locally produced des-(1-3)-IGF-1 may contribute to neuroprotection and gut mucosal integrity. Synthetic production enabled more controlled experimental work. The compound has been investigated in preclinical contexts for applications in muscle preservation, wound healing, and neurological conditions. Its development as a therapeutic agent is an active area of research, with translational and early clinical programs continuing to build the human evidence base.

§07References

• [16]Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1Ross M; Francis G L; Szabo L; Wallace J C; Ballard F J · Biochemical Journal · 1989 ↗